Back Pain News and Research

Latest Back Pain News and Research

Short period of sick leave before lumbar disk herniation surgery yields better results

Back pain and leg pain may be caused by lumbar disk herniation. It may be necessary to treat the condition by surgery, if it persists. Patients who have a short period of sick leave before the surgery are more satisfied with the result of the procedure than those who are off work sick longer. This is the conclusion of a thesis from the University of Gothenburg, Sweden.

14 Jun 2010

Researchers show personal factors play major role in deciding duration of sick leave

Patients, sick-listed for back and neck problems return to work at different rates despite having similar problems, and personal factors play a major role, reveals a thesis from the University of Gothenburg, Sweden.

14 Jun 2010

Phase III study of REVLIMID for treating patients with multiple myeloma shows improvement in PFS

Celgene International Sàrl announced that data from the planned second interim analysis (median follow-up of 21 months) of a phase III, randomized, double-blind study of continuous REVLIMID (lenalidomide) for the treatment of elderly patients with newly diagnosed multiple myeloma show improvement in progression-free survival, the primary endpoint of the study.

14 Jun 2010

Clinical data from investigational study of patients with multiple myeloma presented at ASCO

Celgene International Sàrl announced clinical data from an investigational study of patients with multiple myeloma who were younger than 65 years old and received either lenalidomide (REVLIMID), melphalan and prednisone or melphalan plus autologous stem cell transplant (MEL200) following an induction treatment of lenalidomide plus low-dose dexamethasone (Rd) were presented at the American Society of Clinical Oncology annual meeting.

11 Jun 2010

NuPhysicia's technology solutions provide distinctive medical service

When Healthcare Writer Milt Freudenheim sought real patient care experience in the emerging world of telemedicine for a recent feature article in the New York Times' Sunday Business section, he turned to NuPhysicia, the nation's most experienced video telemedicine services company.

11 Jun 2010

Screen time contributes to headache, backache in school-aged teenagers

The amount of time teenagers spend in front of TV screens and monitors has been associated with physical complaints. A large study of more than 30,000 Nordic teenagers published in the open access journal BMC Public Health has shown that TV viewing, computer use and computer gaming (screen time) were consistently associated with back pain and recurrent headaches.

9 Jun 2010

Final results from Phase 1 trial of OGX-427 for treating solid tumors presented at ASCO 2010

OncoGenex Pharmaceuticals, Inc. today announced final results from a Phase 1 trial. The primary purpose of this trial was to evaluate the safety and tolerability of OGX-427 up to doses of 1000 mg for the treatment of various solid tumors. Patients enrolled had a diagnosis of castrate resistant prostate cancer, breast cancer, ovarian cancer or non-small cell lung cancer.

8 Jun 2010

Researchers present data from Phase II study of lenalidomide in patients with untreated CLL at ASCO

Celgene International Sàrl today announced that researchers presented data from an investigator-initiated Phase II study of lenalidomide (REVLIMID) in untreated patients with chronic lymphocytic leukemia at the annual meeting of the American Society of Clinical Oncology.

8 Jun 2010

Genentech reports results from Phase III study of Avastin in women with advanced ovarian cancer

Genentech, Inc., a wholly owned member of the Roche Group, today announced results from a Phase III study of Avastin (bevacizumab) that showed women with previously untreated advanced ovarian cancer who received Avastin in combination with chemotherapy, followed by the continuation of Avastin alone, had a 39 percent improvement in the likelihood of living longer without the disease worsening (progression-free survival or PFS) compared to chemotherapy alone.

7 Jun 2010

Celgene reports initial data from investigator-initiated study of REVLIMID

Celgene International Sàrl today announced that initial data from an investigator-initiated study of REVLIMID (lenalidomide) plus Rituxan (rituximab) in patients with newly diagnosed indolent B-cell non-Hodgkin's lymphoma (NHL) were presented at the annual meeting of the American Society of Clinical Oncology.

5 Jun 2010

Prismatic eyeglass lenses reduce symptoms associated with TBI, vertical heterophoria: Study

A recent retrospective study by four Michigan physicians shows strong evidence that symptoms of headache, dizziness and anxiety in some patients with traumatic brain injury potentially could be alleviated or even eliminated with specialized eyeglass lenses containing prisms.

5 Jun 2010

Researchers present clinical outcomes of lenalidomide in patients with large B-cell lymphoma

Celgene International Sàrl today announced researchers at the annual meeting of the American Society of Clinical Oncology presented data from an evaluation of lenalidomide (REVLIMID) in patients with diffuse large B-cell lymphoma either with a germinal center B-cell or non-germinal center B-cell phenotype.

5 Jun 2010

Anulex Technologies completes $20M Series E financing round

Anulex Technologies, Inc., a privately held medical device manufacturer focusing on soft tissue Preservation & Anular Repair products, announced the first closing of its fifth round of private equity financing which will total a minimum of $20 million. The Series E round was led by a new unnamed strategic investor with participation from existing investors Affinity Capital, Delphi Ventures, MB Venture Partners, New Enterprise Associates, SightLine Partners and Split Rock Partners.

4 Jun 2010

Tips to prevent back injuries

Whether moving to a new home or packing up for the semester, the physical intensity of moving can be extreme. Packing boxes, moving heavy furniture, emptying overhead cabinets -- all come with some risk for injury, especially to your back. Back pain is one of the most common reasons for Americans visit their doctors.

3 Jun 2010

Alexion Pharmaceuticals plans to launch Soliris in Japan for patients with PNH

Alexion Pharmaceuticals, Inc. and Alexion Pharma International Sàrl today announced that the launch of Soliris (eculizumab) as a treatment for patients with PNH in Japan will begin in the third quarter of 2010, approximately three months earlier than previously expected.

2 Jun 2010

Amgen's Prolia receives FDA approval for treatment of postmenopausal women with osteoporosis

Amgen Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Prolia™ (denosumab) for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. Prolia, the first and only FDA-approved RANK Ligand inhibitor, is an every six month 60 mg subcutaneous injection administered by a health care professional.

2 Jun 2010

FDA approves Prolia for postmenopausal women with osteoporosis

The U.S. Food and Drug Administration approved Prolia, an injectable treatment for postmenopausal women with osteoporosis who are at high risk for fractures.

2 Jun 2010

Dendreon announces data presentation from 4 PROVENGE clinical trials at 105th AUA annual meeting

Dendreon Corporation today announced the presentation of safety data from the integrated analysis of four randomized PROVENGE® (sipuleucel-T) clinical trials of an autologous cellular immunotherapy in prostate cancer at the 105th Annual Scientific Meeting of the American Urological Association (AUA) in San Francisco.

1 Jun 2010

Smartfish announces second distribution partnership with Mobility Lab for ErgoMotion technology

Today from Medpi 2010, Smartfish Technologies announced its second strategic partnership to distribute and sell its ErgoMotion™ technology with Mobility Lab of France. As part of its agreement with Mobility Lab, Smartfish will provide its award-winning ErgoMotion technology to Mobility Lab for distribution to retailers in France, Switzerland, Netherlands, Belgium, Luxemburg and Spain. Smartfish will manufacture the resulting Mobility Lab branded products powered by ErgoMotion.

28 May 2010

Genentech to present new data for targeted cancer medicines at 46th ASCO

Genentech, Inc., a wholly owned member of the Roche Group, today announced that it will present new data for its targeted cancer medicines and the way they may be used in several different cancer types at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). Approximately 400 abstracts featuring Genentech and Roche's cancer medicines and investigational agents across 30 cancer types will be presented during the meeting that is taking place June 4 to 8, 2010 in Chicago.

21 May 2010

Back Pain News and Research

Latest Back Pain News and Research

Short period of sick leave before lumbar disk herniation surgery yields better results

Researchers show personal factors play major role in deciding duration of sick leave

Phase III study of REVLIMID for treating patients with multiple myeloma shows improvement in PFS

Clinical data from investigational study of patients with multiple myeloma presented at ASCO

NuPhysicia's technology solutions provide distinctive medical service

Screen time contributes to headache, backache in school-aged teenagers

Final results from Phase 1 trial of OGX-427 for treating solid tumors presented at ASCO 2010

Researchers present data from Phase II study of lenalidomide in patients with untreated CLL at ASCO

Genentech reports results from Phase III study of Avastin in women with advanced ovarian cancer

Celgene reports initial data from investigator-initiated study of REVLIMID

Prismatic eyeglass lenses reduce symptoms associated with TBI, vertical heterophoria: Study

Researchers present clinical outcomes of lenalidomide in patients with large B-cell lymphoma

Anulex Technologies completes $20M Series E financing round

Tips to prevent back injuries

Alexion Pharmaceuticals plans to launch Soliris in Japan for patients with PNH

Amgen's Prolia receives FDA approval for treatment of postmenopausal women with osteoporosis

FDA approves Prolia for postmenopausal women with osteoporosis

Dendreon announces data presentation from 4 PROVENGE clinical trials at 105th AUA annual meeting

Smartfish announces second distribution partnership with Mobility Lab for ErgoMotion technology

Genentech to present new data for targeted cancer medicines at 46th ASCO

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Back Pain News and Research

Latest Back Pain News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in